Market Data 
Markets
Replies to post #105753 on Biotech Values
10/07/10 8:56 AM
Having full ownership of danoprevir increases our ability to rapidly develop combinations of our own hepatitis C compounds with molecules from other companies to maximize patient benefit."
10/10/10 11:16 AM
Well, Terence, we have filed a redacted version of our contract with Roche in our 2006 10-K filed in April or so of 2007. I will direct you to sections of the contract that are appropriate to exclusivity. But as you will see if you read that, you will find that we have an exclusivity to each other for the mechanism of action that is protease inhibition. And there are consequences, should that exclusivity be broken. And so, I would encourage you to look at the disclosure. And we feel very confident and very comfortable in our position that Roche is committed to 191 and has an exclusivity agreement with pretty important consequences to them, should that agreement be broken.
AI
